Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + topotecan + filgrastim
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination chemotherapy regimen was evaluated in a Phase II clinical trial conducted at M.D. Anderson Cancer Center for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma (NHL). The regimen consists of **paclitaxel**, a microtubule-stabilizing agent that arrests the cell cycle in the G2/M phase; **topotecan**, a topoisomerase I inhibitor that induces lethal DNA double-strand breaks during replication; and **filgrastim-SD/01**, a granulocyte colony-stimulating factor (G-CSF) used as supportive care to accelerate neutrophil recovery following intensive chemotherapy. This salvage therapy was specifically developed for patients who had previously failed standard anthracycline- or platinum-based chemotherapy regimens.
- Brand names
- TaxolHycamtin
- Other names
- Paclitaxel and Topotecan with Filgrastim-SD/01 supportPaclitaxel and Topotecan with Filgrastim-SD/01 in Aggressive NHL
02
Targets
TUBB (Tubulin (alpha and beta subunits))CSF3R (Granulocyte colony-stimulating factor receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on paclitaxel + topotecan + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + topotecan + filgrastim.